Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections

Valerie J. Waters; Timothy J. Kidd; Rafael Canton; Miquel B. Ekkelenkamp; Helle Krogh Johansen; John J. Lipuma; Scott C. Bell; J. Stuart Elborn; Patrick A. Flume; Donald R. Vandevanter; Peter Gilligan; Wendy Bullington; Pierre Regis Burgel; Catherine Byrnes; Pavel Drevinek; Alison Holmes; Barbara Kahl; Holly Maples; Stacey Martiniano; Susanna McColley; Andrew Morris; Marianne Muhlebach; Michael Parkins; Felix Ratjen; Jason Roberts; Lisa Saiman; Anand Shah; Alan Smyth; Ranjani Somayaji; Giovanni Taccetti; Michael Tunney; Kevin Winthrop; Edith Zemanick

doi:10.1093/cid/ciz364

Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections

Valerie J. Waters, Timothy J. Kidd, Rafael Canton, Miquel B. Ekkelenkamp, Helle Krogh Johansen, John J. Lipuma, Scott C. Bell, J. Stuart Elborn, Patrick A. Flume, Donald R. Vandevanter, Peter Gilligan, Wendy Bullington, Pierre Regis Burgel, Catherine Byrnes, Pavel Drevinek, Alison Holmes, Barbara Kahl, Holly Maples, Stacey Martiniano, Susanna McColleyAndrew Morris, Marianne Muhlebach, Michael Parkins, Felix Ratjen, Jason Roberts, Lisa Saiman, Anand Shah, Alan Smyth, Ranjani Somayaji, Giovanni Taccetti, Michael Tunney, Kevin Winthrop, Edith Zemanick

School Of Public Health

Research output: Contribution to journal › Review article › peer-review

56 Scopus citations

Abstract

Median cystic fibrosis (CF) survival has increased dramatically over time due to several factors, including greater availability and use of antimicrobial therapies. During the progression of CF lung disease, however, the emergence of multidrug antimicrobial resistance can limit treatment effectiveness, threatening patient longevity. Current planktonic-based antimicrobial susceptibility testing lacks the ability to predict clinical response to antimicrobial treatment of chronic CF lung infections. There are numerous reasons for these limitations including bacterial phenotypic and genotypic diversity, polymicrobial interactions, and impaired antibiotic efficacy within the CF lung environment. The parallels to other chronic diseases such as non-CF bronchiectasis are discussed as well as research priorities for moving forward.

Original language	English (US)
Pages (from-to)	1812-1816
Number of pages	5
Journal	Clinical Infectious Diseases
Volume	69
Issue number	10
DOIs	https://doi.org/10.1093/cid/ciz364
State	Published - Nov 15 2019

Keywords

antimicrobial susceptibility
cystic fibrosis

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciz364

Cite this

Waters, V. J., Kidd, T. J., Canton, R., Ekkelenkamp, M. B., Johansen, H. K., Lipuma, J. J., Bell, S. C., Elborn, J. S., Flume, P. A., Vandevanter, D. R., Gilligan, P., Bullington, W., Burgel, P. R., Byrnes, C., Drevinek, P., Holmes, A., Kahl, B., Maples, H., Martiniano, S., ... Zemanick, E. (2019). Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clinical Infectious Diseases, 69(10), 1812-1816. https://doi.org/10.1093/cid/ciz364

Waters, VJ, Kidd, TJ, Canton, R, Ekkelenkamp, MB, Johansen, HK, Lipuma, JJ, Bell, SC, Elborn, JS, Flume, PA, Vandevanter, DR, Gilligan, P, Bullington, W, Burgel, PR, Byrnes, C, Drevinek, P, Holmes, A, Kahl, B, Maples, H, Martiniano, S, McColley, S, Morris, A, Muhlebach, M, Parkins, M, Ratjen, F, Roberts, J, Saiman, L, Shah, A, Smyth, A, Somayaji, R, Taccetti, G, Tunney, M, Winthrop, K & Zemanick, E 2019, 'Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections', Clinical Infectious Diseases, vol. 69, no. 10, pp. 1812-1816. https://doi.org/10.1093/cid/ciz364

@article{c89863c66c5e41df96667898e0c82df6,

title = "Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections",

abstract = "Median cystic fibrosis (CF) survival has increased dramatically over time due to several factors, including greater availability and use of antimicrobial therapies. During the progression of CF lung disease, however, the emergence of multidrug antimicrobial resistance can limit treatment effectiveness, threatening patient longevity. Current planktonic-based antimicrobial susceptibility testing lacks the ability to predict clinical response to antimicrobial treatment of chronic CF lung infections. There are numerous reasons for these limitations including bacterial phenotypic and genotypic diversity, polymicrobial interactions, and impaired antibiotic efficacy within the CF lung environment. The parallels to other chronic diseases such as non-CF bronchiectasis are discussed as well as research priorities for moving forward.",

keywords = "antimicrobial susceptibility, cystic fibrosis",

author = "Waters, {Valerie J.} and Kidd, {Timothy J.} and Rafael Canton and Ekkelenkamp, {Miquel B.} and Johansen, {Helle Krogh} and Lipuma, {John J.} and Bell, {Scott C.} and Elborn, {J. Stuart} and Flume, {Patrick A.} and Vandevanter, {Donald R.} and Peter Gilligan and Wendy Bullington and Burgel, {Pierre Regis} and Catherine Byrnes and Pavel Drevinek and Alison Holmes and Barbara Kahl and Holly Maples and Stacey Martiniano and Susanna McColley and Andrew Morris and Marianne Muhlebach and Michael Parkins and Felix Ratjen and Jason Roberts and Lisa Saiman and Anand Shah and Alan Smyth and Ranjani Somayaji and Giovanni Taccetti and Michael Tunney and Kevin Winthrop and Edith Zemanick",

year = "2019",

month = nov,

day = "15",

doi = "10.1093/cid/ciz364",

language = "English (US)",

volume = "69",

pages = "1812--1816",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections

AU - Waters, Valerie J.

AU - Kidd, Timothy J.

AU - Canton, Rafael

AU - Ekkelenkamp, Miquel B.

AU - Johansen, Helle Krogh

AU - Lipuma, John J.

AU - Bell, Scott C.

AU - Elborn, J. Stuart

AU - Flume, Patrick A.

AU - Vandevanter, Donald R.

AU - Gilligan, Peter

AU - Bullington, Wendy

AU - Burgel, Pierre Regis

AU - Byrnes, Catherine

AU - Drevinek, Pavel

AU - Holmes, Alison

AU - Kahl, Barbara

AU - Maples, Holly

AU - Martiniano, Stacey

AU - McColley, Susanna

AU - Morris, Andrew

AU - Muhlebach, Marianne

AU - Parkins, Michael

AU - Ratjen, Felix

AU - Roberts, Jason

AU - Saiman, Lisa

AU - Shah, Anand

AU - Smyth, Alan

AU - Somayaji, Ranjani

AU - Taccetti, Giovanni

AU - Tunney, Michael

AU - Winthrop, Kevin

AU - Zemanick, Edith

PY - 2019/11/15

Y1 - 2019/11/15

N2 - Median cystic fibrosis (CF) survival has increased dramatically over time due to several factors, including greater availability and use of antimicrobial therapies. During the progression of CF lung disease, however, the emergence of multidrug antimicrobial resistance can limit treatment effectiveness, threatening patient longevity. Current planktonic-based antimicrobial susceptibility testing lacks the ability to predict clinical response to antimicrobial treatment of chronic CF lung infections. There are numerous reasons for these limitations including bacterial phenotypic and genotypic diversity, polymicrobial interactions, and impaired antibiotic efficacy within the CF lung environment. The parallels to other chronic diseases such as non-CF bronchiectasis are discussed as well as research priorities for moving forward.

AB - Median cystic fibrosis (CF) survival has increased dramatically over time due to several factors, including greater availability and use of antimicrobial therapies. During the progression of CF lung disease, however, the emergence of multidrug antimicrobial resistance can limit treatment effectiveness, threatening patient longevity. Current planktonic-based antimicrobial susceptibility testing lacks the ability to predict clinical response to antimicrobial treatment of chronic CF lung infections. There are numerous reasons for these limitations including bacterial phenotypic and genotypic diversity, polymicrobial interactions, and impaired antibiotic efficacy within the CF lung environment. The parallels to other chronic diseases such as non-CF bronchiectasis are discussed as well as research priorities for moving forward.

KW - antimicrobial susceptibility

KW - cystic fibrosis

UR - http://www.scopus.com/inward/record.url?scp=85073192268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073192268&partnerID=8YFLogxK

U2 - 10.1093/cid/ciz364

DO - 10.1093/cid/ciz364

M3 - Review article

C2 - 31056660

AN - SCOPUS:85073192268

SN - 1058-4838

VL - 69

SP - 1812

EP - 1816

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 10

ER -

Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this